Nectar Lifesciences

Chandigarh, India Founded: 1995 • Age: 31 yrs Listed
Cephalosporin APIs and generic formulations are manufactured.
Request Access
Report Incorrect Data
Page last updated

About Nectar Lifesciences

Nectar Lifesciences is a publicly listed company based in Chandigarh (India) founded in 1995. Cephalosporin APIs and generic formulations are manufactured. Nectar Lifesciences has raised $46.85 million across 1 funding round from investors including NSR Partners. The company has 1,408 employees. Its chief executive, as recorded, is Amit Chadah. Its Indian entity Nectar Life Sciences Limited reported revenue of ₹9.29 Cr. Nectar Lifesciences offers products and services including Cephalosporin APIs, Formulations, and Empty Hard Gelatin Capsules. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation.

Company details

Nectar Lifesciences was founded in 1995 and is headquartered in Chandigarh, India. Operations in the pharmaceutical sector involve the production of cephalosporin active pharmaceutical ingredients and generic formulations. Additional offerings include contract research and manufacturing services, hard gelatin capsules, in vitro diagnostics, and natural extracts such as menthol and mint derivatives along with guar gum. Focus remains on core pharmaceutical manufacturing and related services.

  • Headquarters Chandigarh, India
  • Employees 1,408
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Phone
    •••• ••••
  • Website neclife.com
  • Social LinkedIn
  • Legal Name Nectar Lifesciences Ltd.
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹199 Cr

    NECLIFE · NSE

  • Share Price
    ₹10.25

    -0.29% today

  • EBITDA
    −₹296 Cr

    FY 2025-26

  • Net Profit
    −₹241 Cr

    FY 2025-26 · -111.6% YoY

  • ROE
    -31.3%

    ROCE 0.1%

  • Debt / Equity
    0.38

    Interest cover -12.2x

  • Total Equity Funding
    $46.85M (USD)

    in 1 rounds

  • Latest Funding Round
    $46.85M (USD), Private Equity Round

    Mar 2010

  • Investors
    NSR Partners
  • Employee Count
    1,408

Products & Services of Nectar Lifesciences

Nectar Lifesciences offers a comprehensive portfolio of products and services, including Cephalosporin APIs, Formulations, and Empty Hard Gelatin Capsules.

Cephalosporin APIs
Pharmaceutical Ingredients

Manufactures antibiotics like Cefixime for global healthcare needs.

Formulations
Drug Manufacturing

Produces tablets, capsules, and injectables for pharmaceutical use.

Empty Hard Gelatin Capsules
Packaging Solutions

Provides capsules for formulation in pharmaceutical applications.

Funding Insights of Nectar Lifesciences

Nectar Lifesciences has successfully raised a total of $46.85M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $46.85 million completed in March 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $46.85M
  • Total Rounds 1
  • Last Round Private Equity Round — $46.85M
  • First Round $46.85M

    (Mar 2010)

  • Investors Count 1

All 1 funding rounds of Nectar Lifesciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2010$46.85MPrivate Equity Round––
NSR Partners
Valuation history

1 investors in total: 1 institutional.

Investors in Nectar Lifesciences

Nectar Lifesciences has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include NSR Partners.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
NSR Partners
Growth-stage private equity investments are pursued across sectors.
nsrpartners.comNew York, United States
Premium access

Investor details for Nectar Lifesciences

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Nectar Life Sciences Limited (Nectar Lifesciences)

Nectar Life Sciences Limited is the primary company behind Nectar Lifesciences. The board of Nectar Life Sciences Limited currently have 6 directors; the longest-serving is Sanjiv Goyal, appointed in 1995. 26 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sanjiv Goyal
DIN 00002841
Managing Director27 Jun 199531 yrs 4 moNectar Life Sciences Limited
Rupinder Tewari
DIN 07009485
Director11 Feb 20197 yrs 8 moNectar Life Sciences Limited
Kuldip Kumar Bhasin
DIN 09250008
Director21 Sep 20215 yrs 1 moNectar Life Sciences Limited
Indu Pal Kaur
DIN 09686862
Director02 Aug 20224 yrs 3 moNectar Life Sciences Limited
Surulichamy Senthilkumar
DIN 11124083
Director10 Nov 20251 yrNectar Life Sciences Limited
Sushil Kapoor
DIN 00063525
Whole-time director04 Dec 202511 moNectar Life Sciences Limited

People of Nectar Lifesciences

30 people are tracked at Nectar Lifesciences (8 in leadership, 22 in team); the tracked headcount is 1,408.

NameRoleGroup
Amit Chadah
CEOLeadership
Akshay Mishra
Plant Head-sr G M Plant OperationsLeadership
Subhash Sharma
President Business Development (india)Leadership
Sanjiv Goyal
Chairman & Managing DirectorLeadership
Sushil Kapoor
Chief Financial OfficerLeadership
Dr. Prabhat Kumar Sahoo
Vice President ( R & D )Leadership
Jatinder Sharma
Senior General ManagerLeadership
Satinder Singh
Dy General ManagerLeadership
Subodh Dubey
AGM (generic Division)Team
Mohit Sharma
Instrumentation EngineerTeam
Pallvi Thakur
Export Executive LogisticsTeam
Kamlesh Vishwakarma
Supply Chain ManagerTeam
Ca Mohit Garg
Accounts Taxation ManagerTeam
Pankaj Tripathi
MicrbiologistTeam
Avtar Singh
Human Resources ExecutiveTeam
Parveen Bhardwaj
ExecutiveTeam
Dr.rishi Pratap Singh
Group Leader R&dTeam
Miss Ujval Gaonkar
R&d And Production ManagerTeam
Shiwani Gupta
Human Resources OfficerTeam
Pavan Raju
Senior Research Associate (formulation Scientist)Team

10 more people are available in the full profile.

Premium access

Complete people profiles for Nectar Lifesciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Nectar Lifesciences

Nectar Lifesciences is a publicly listed company on the NSE with ticker symbol NECLIFE in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date18 Jul 2005
  • Listed onNSE: NECLIFE · BSE: 532649
  • Listed entityNectar Lifesciences Ltd.
  • Exchange sectorHealth technology
  • ISININE023H01027
  • Share price₹10.15 · 2026-10-14
  • Market capitalisation₹198 Cr
  • EPS (diluted, trailing year)₹-11.38
  • Volume (last session)22,926

Financials of Nectar Lifesciences

Exchange-reported figures of Nectar Life Sciences Limited, the listed company behind Nectar Lifesciences (NSE: NECLIFE).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹0.00 Cr
-100.0% YoY
EBITDA
−₹296 Cr
-902.2% YoY
Profit After Tax
−₹241 Cr
-111.6% YoY
Net Worth
₹582 Cr
-39.1% YoY
Total Assets
₹596 Cr
-61.5% YoY
Total Debt
Nil

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue0.001,6701,6841,5241,6691,5432,366
Revenue growth-100.0%-0.8%+10.5%-8.7%+8.1%-34.8%-
EBITDA(296)(29.56)15253.0115983.72220
EBITDA margin--1.8%+9.0%+3.5%+9.5%+5.4%+9.3%
Profit before tax(323)(162)18.27(42.42)34.07(84.78)37.46
Net profit(241)(114)4.88(64.69)18.12(47.87)31.56
Net profit margin--6.8%+0.3%-4.3%+1.1%-3.1%+1.3%
EPS (₹)(15.08)(5.07)0.22(1.08)1.12(3.27)1.42
Balance sheet
Total assets5961,5481,7131,8261,9561,9761,926
Net worth5829561,0691,0651,0881,0621,136
Total debt0.00582636754860903779
Cash & bank11219.2219.8117.5817.8125.5421.29
Net working capital2147378068679198261,024
Cash flow
Cash from operations(349)16922513495.0121.38285
Cash from investing1,208(41.93)(17.03)51.7016.64(28.62)(33.13)
Cash from financing(767)(128)(205)(186)(119)11.49(252)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue0.441.290.000.715.240.010.015.74
Revenue growth (YoY)-91.6%--100.0%-87.6%-98.5%---
Other income3.246.2935.460.030.320.188.086.52
EBITDA(27.27)(87.95)(1.92)(176)(63.39)(130)(0.04)(0.58)
EBITDA margin-----1212.0%---10.1%
Depreciation0.110.080.060.110.530.300.070.45
Interest0.165.9030.220.000.000.000.000.00
Profit before tax(24.30)(87.64)3.26(176)(63.60)(130)7.975.49
Tax(8.90)(19.72)(11.02)0.16(0.37)(0.06)0.12(0.12)
Net profit(15.40)(67.92)14.28(176)(63.23)(130)7.855.61
EPS (₹)(0.79)(3.38)0.64(7.85)(2.82)(5.80)0.350.25
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue0.000.001,6841,5241,6681,5422,363
Revenue growth--100.0%+10.5%-8.7%+8.2%-34.8%-
EBITDA(296)(115)15254.7315983.82218
EBITDA margin--+9.0%+3.6%+9.5%+5.4%+9.2%
Profit before tax(323)(113)18.28(40.69)34.35(84.67)35.75
Net profit(241)(114)4.83(62.96)15.91(47.76)29.85
Net profit margin--+0.3%-4.1%+1.0%-3.1%+1.3%
EPS (₹)(15.08)(5.07)0.22(1.00)1.13(3.26)1.34
Balance sheet
Total assets5861,5481,7131,8261,9551,9751,925
Net worth5829561,0691,0651,0871,0611,135
Total debt0.00582636754860903779
Cash & bank10819.2219.8017.5717.7425.4321.23
Net working capital2117378068679188251,023
Cash flow
Cash from operations(417)16922513395.0421.33286
Cash from investing1,205(41.93)(17.03)52.0316.64(28.62)(33.14)
Cash from financing(699)(128)(205)(186)(119)11.49(252)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue0.441.290.005.715.240.014555.74
Revenue growth (YoY)-91.6%--100.0%-0.5%-98.5%---
Other income6.176.2935.460.030.320.180.576.52
Total expenses27.6889.231.9218268.631304106.32
EBITDA(27.24)(87.94)(1.92)(176)(63.39)(130)44.71(0.58)
EBITDA margin----3520.2%-1212.0%-+9.8%-10.1%
Depreciation0.110.080.060.200.530.3015.610.45
Interest0.165.9030.220.000.000.0017.120.00
Profit before tax(21.34)(87.63)3.26(176)(63.60)(130)12.555.49
Tax(8.20)(19.71)(11.02)(0.18)(0.37)(0.06)4.71(0.12)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue0.441.290.000.715.240.010.015.74
Revenue growth (YoY)-91.6%--100.0%-87.6%-98.5%---
Other income3.246.2935.460.030.320.188.086.52
EBITDA(27.27)(87.95)(1.92)(176)(63.39)(130)(0.04)(0.58)
EBITDA margin-----1212.0%---10.1%
Depreciation0.110.080.060.110.530.300.070.45
Interest0.165.9030.220.000.000.000.000.00
Profit before tax(24.30)(87.64)3.26(176)(63.60)(130)7.975.49
Tax(8.90)(19.72)(11.02)0.16(0.37)(0.06)0.12(0.12)
Net profit(15.40)(67.92)14.28(176)(63.23)(130)7.855.61
EPS (₹)(0.79)(3.38)0.64(7.85)(2.82)(5.80)0.350.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue0.001,6701,6841,5241,6691,5432,366
Revenue growth-100.0%-0.8%+10.5%-8.7%+8.1%-34.8%-
Other income9.294.9914.5843.1811.323.794.36
Total expenses2961,7001,5331,4711,5101,4602,147
Employee cost0.9093.6181.7175.1371.9170.5978.19
EBITDA(296)(29.56)15253.0115983.72220
EBITDA margin--1.8%+9.0%+3.5%+9.5%+5.4%+9.3%
Depreciation0.3462.3960.7259.1256.9760.2560.77
Interest36.1374.5887.1479.4978.81112126
Profit before tax(323)(162)18.27(42.42)34.07(84.78)37.46
Tax(30.53)(47.85)13.28(18.24)9.03(11.50)5.68
Net profit(241)(114)4.88(64.69)18.12(47.87)31.56
Net profit margin--6.8%+0.3%-4.3%+1.1%-3.1%+1.3%
EPS (₹)(15.08)(5.07)0.22(1.08)1.12(3.27)1.42
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital19.4322.4322.4322.4322.4322.4322.43
Reserves & surplus5639341,0471,0421,0651,0401,114
Shareholders' funds (net worth)5829561,0691,0651,0881,0621,136
Minority interest0.000.000.000.000.000.000.00
Secured loans0.00487540672784840760
Unsecured loans0.0094.6896.0181.4576.0863.1718.45
Total debt0.00582636754860903779
Total liabilities5961,5481,7131,8261,9561,9761,926
Assets
Gross block1071,6521,5991,5581,5631,5561,509
Net block105633643662723772785
Capital work in progress0.0056.7365.7577.7885.1098.63115
Investments13.210.770.730.550.700.690.40
Inventories0.30690709673660588978
Sundry debtors0.00345379280447375396
Cash & bank balances11219.2219.8117.5817.8125.5421.29
Loans & advances128182175261230250220
Total current assets2401,2371,2831,2311,3541,2381,615
Total current liabilities26.06500478364435412591
Net working capital2147378068679198261,024
Total assets5961,5481,7131,8261,9561,9761,926
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash19.2219.8117.5817.8125.5421.2921.33
Net cash from operating activities(349)16922513495.0121.38285
Net cash from investing activities1,208(41.93)(17.03)51.7016.64(28.62)(33.13)
Net cash from financing activities(767)(128)(205)(186)(119)11.49(252)
Net change in cash92.91(0.58)2.23(0.23)(7.73)4.25(0.03)
Closing cash11219.2219.8117.5817.8125.5421.29
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-100.0%-0.8%+10.5%-8.7%+8.1%-34.8%-
EBITDA growth-902.2%-119.5%+185.9%-66.6%+89.4%-61.9%-
PBT growth-100.2%-+9998.0%-+9998.0%--36.3%
Net income growth-111.6%-2430.1%+107.5%-457.0%+137.9%-251.7%-
Revenue CAGR (3Y)-100.0%+0.0%+3.0%-13.7%-15.7%-6.3%+12.9%
EBITDA CAGR (3Y)--+21.9%-37.7%-15.7%-29.2%-0.7%
Profitability & leverage
Net income margin--6.8%+0.3%-1.6%+1.5%-4.8%+1.3%
Return on capital employed+0.1%-5.3%+6.0%-0.2%+5.3%+2.7%+8.3%
Return on net worth-31.3%-11.2%+0.5%-6.0%+1.7%-4.4%+2.8%
Debt / equity0.380.600.650.750.820.770.75
Long-term debt / equity0.050.100.170.240.200.110.13
Interest cover-12.18-81.1195.94-1,300.9877.60477.3879.17
Efficiency & per share
Fixed asset turnover0.001.171.221.121.231.151.76
Inventory turnover0.002.732.792.623.092.252.79
Debtors turnover0.005.275.854.814.694.585.54
EPS (₹)(15.08)(5.07)0.22(1.08)1.12(3.27)1.42
Dividend per share (₹)0.000.000.000.000.000.000.05
Book value per share (₹)29.9842.6347.6847.4748.5147.3650.66
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue0.441.290.005.715.240.014555.74
Revenue growth (YoY)-91.6%--100.0%-0.5%-98.5%---
Other income6.176.2935.460.030.320.180.576.52
Total expenses27.6889.231.9218268.631304106.32
EBITDA(27.24)(87.94)(1.92)(176)(63.39)(130)44.71(0.58)
EBITDA margin----3520.2%-1212.0%-+9.8%-10.1%
Depreciation0.110.080.060.200.530.3015.610.45
Interest0.165.9030.220.000.000.0017.120.00
Profit before tax(21.34)(87.63)3.26(176)(63.60)(130)12.555.49
Tax(8.20)(19.71)(11.02)(0.18)(0.37)(0.06)4.71(0.12)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue0.000.001,6841,5241,6681,5422,363
Revenue growth--100.0%+10.5%-8.7%+8.2%-34.8%-
Other income9.291.8814.5843.1811.323.794.32
Total expenses2961151,5331,4691,5091,4582,145
Employee cost0.890.0981.7175.1471.9170.5578.19
EBITDA(296)(115)15254.7315983.82218
EBITDA margin--+9.0%+3.6%+9.5%+5.4%+9.2%
Depreciation0.340.6260.7259.1256.9760.2560.77
Interest36.130.0087.1479.4878.81112126
Profit before tax(323)(113)18.28(40.69)34.35(84.67)35.75
Tax(30.53)0.3813.27(18.24)9.03(11.50)5.68
Net profit(241)(114)4.83(62.96)15.91(47.76)29.85
Net profit margin--+0.3%-4.1%+1.0%-3.1%+1.3%
EPS (₹)(15.08)(5.07)0.22(1.00)1.13(3.26)1.34
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital19.4322.4322.4322.4322.4322.4322.43
Reserves & surplus5639341,0471,0421,0641,0381,112
Shareholders' funds (net worth)5829561,0691,0651,0871,0611,135
Secured loans0.00487540672784825760
Unsecured loans0.0094.6896.0181.4476.0877.9918.45
Total debt0.00582636754860903779
Total liabilities5861,5481,7131,8261,9551,9751,925
Assets
Gross block5.911,6521,5991,5581,5631,5561,509
Net block3.45633643662723772785
Capital work in progress0.0056.7365.7577.7885.1098.63115
Investments13.460.770.740.561.031.030.74
Inventories0.30690709673660587975
Sundry debtors0.00345379280447375397
Cash & bank balances10819.2219.8017.5717.7425.4321.23
Loans & advances128182175261229250220
Total current assets2371,2371,2831,2311,3531,2371,614
Total current liabilities25.97500478364435412591
Net working capital2117378068679188251,023
Total assets5861,5481,7131,8261,9551,9751,925
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash19.2219.8017.5717.7425.4321.2320.58
Net cash from operating activities(417)16922513395.0421.33286
Net cash from investing activities1,205(41.93)(17.03)52.0316.64(28.62)(33.14)
Net cash from financing activities(699)(128)(205)(186)(119)11.49(252)
Net change in cash88.91(0.58)2.23(0.17)(7.70)4.200.65
Closing cash10819.2219.8017.5717.7425.4321.23
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth--100.0%+10.5%-8.7%+8.2%-34.8%-
EBITDA growth-158.6%-175.6%+176.9%-65.5%+89.5%-61.6%-
PBT growth-185.4%-+9998.0%-+9998.0%--39.0%
Net income growth-111.6%-2454.7%+107.7%-495.7%+133.3%-260.0%-
Revenue CAGR (3Y)-100.0%-100.0%+3.0%-13.6%-15.7%-6.3%+12.9%
EBITDA CAGR (3Y)--+21.8%-36.9%-15.6%-29.2%-0.9%
Profitability & leverage
Net income margin--+0.3%-1.5%+1.5%-4.8%+1.3%
Return on capital employed+0.1%+0.1%+6.0%-0.1%+5.3%+2.7%+8.2%
Return on net worth-31.3%-11.2%+0.5%-5.9%+1.5%-4.4%+2.7%
Debt / equity0.380.600.650.750.820.770.75
Long-term debt / equity0.040.100.170.240.200.110.13
Interest cover-12.180.0095.93-1,810.4877.39475.3180.01
Efficiency & per share
Fixed asset turnover0.000.001.221.121.231.151.76
Inventory turnover0.000.002.792.623.092.262.79
Debtors turnover0.000.005.854.814.694.575.51
EPS (₹)(15.08)(5.07)0.22(1.00)1.13(3.26)1.34
Dividend per share (₹)0.000.000.000.000.000.000.05
Book value per share (₹)29.9842.6347.6847.4748.4647.3050.59

Timeline of Nectar Lifesciences

3 dated milestones of Nectar Lifesciences across 15 years, from founding to its latest funding, stage changes and deals.

  1. Founded Nectar Lifesciences is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $46.9M.

Web traffic of Nectar Lifesciences

The website of Nectar Lifesciences (neclife.com) receives about 4.6K visits a month and ranks #4,844,386 among all websites worldwide, #5,687 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    4.6K

    ▲ 31.1% vs previous month

  • Unique visitors
    1.5K

    per month

  • Global rank
    #4,844,386

    among all websites

  • Category rank
    #5,687

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Nectar Lifesciences. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Rousselot
rousselot.com
100%
1.4K#10,872,681View details
Menarini Group
menarini.com
96%
#831,383View details
PMRS
pmrsinc.com
95%
#9,928,941View details
Surepharm
surepharm.com
94%
View details
Recipharm
recipharm.com
94%
21.8K#1,103,989View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 11 similar websites and full traffic analytics for Nectar Lifesciences

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 11 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Nectar Lifesciences (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Nectar Lifesciences

Nectar Lifesciences To Acquire 100% Paid- Up Equity Share Capital Of Avensis Exports
Reuters • 8 months ago
Nectar Lifesciences Approves Buyback Of Shares Valued At 810 Million Rupees
Reuters • 11 months ago
India's Nectar Lifesciences jumps on plan to consider buyback of shares
Reuters • 11 months ago
Nectar Lifesciences Proposes Buyback Of Equity Shares
Reuters • 11 months ago
Nectar Lifesciences Says Secured Debt And Interest Owed By Co Fully Repaid And Settled With Banks
Reuters • 1 year ago
Graft case: CBI officer who sought Honda City car as bribe convicted in Chandigarh | Chandigarh News - The Indian Express
The Indian Express • 1 year ago
Nectar Lifesciences Says Investment Agreement With Isengard Direct PE LLC Stands Terminated
Reuters • 1 year ago
Nectar Lifesciences Sept-Quarter Consol Profit From Continuing Operations 56 Million Rupees
Reuters • 1 year ago
Breakout stocks to buy or sell: Ashoka Buildcon to Nandan Denim — Sumeet Bagadia recommends five shares to buy today
Livemint • 2 years ago
Nectar Lifesciences June-Quarter Consol Profit From Cont Ops 29.7 Million Rupees
Reuters • 2 years ago
Premium access

Complete news archive for Nectar Lifesciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nectar Lifesciences

Nectar Lifesciences was founded in 1995 and raised its 1st funding round 15 years after it was founded.

Nectar Lifesciences is headquartered in Chandigarh, India.

Amit Chadah is the CEO of Nectar Lifesciences, as recorded in our data.

Nectar Lifesciences is a funded company, having raised a total of $46.85M across 1 funding round to date. The company's 1st funding round was a Private Equity Round of $46.85M, raised on Mar 2010.

Nectar Lifesciences has 1,408 employees.

The primary company behind Nectar Lifesciences, Nectar Life Sciences Limited, reported revenue of ₹9.29 Cr for FY 2026, up 9997% year on year.

Nectar Lifesciences was founded in 1995 and is headquartered in Chandigarh, India. Operations in the pharmaceutical sector involve the production of cephalosporin active pharmaceutical ingredients and generic formulations. Additional offerings include contract research and manufacturing services, hard gelatin capsules, in vitro diagnostics, and natural extracts such as menthol and mint derivatives along with guar gum. Focus remains on core pharmaceutical manufacturing and related services.

Nectar Lifesciences offers Cephalosporin APIs, Formulations, and Empty Hard Gelatin Capsules.

Yes, Nectar Lifesciences is publicly traded on NSE under the ticker symbol NECLIFE.

Nectar Lifesciences has 1 investor. Key investors include NSR Partners.

Nectar Lifesciences operates through Nectar Life Sciences Limited.

The legal entities of Nectar Lifesciences currently have 7 directors, including Indu Pal Kaur, Rupinder Tewari, Kuldip Kumar Bhasin and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available